1. Introduction {#sec1-cancers-11-00253}
===============

Breast cancer surgery is adapting to rising patient preferences for breast reconstructive procedures. Treatment of breast cancer surgery can be classified into two overall groups: breast conserving therapy (BCT) including partial mastectomy (PM) and oncoplastic surgery (OPS), and mastectomy (MAST) including mastectomy alone (M) and M with breast reconstruction (M + R). From 2005 to 2017, the use of breast reconstruction significantly increased compared to other types of breast cancer surgery for patients with both ductal carcinoma in situ (DCIS) and invasive carcinoma (IvBC) \[[@B1-cancers-11-00253]\]. Known for its extensive use of tissue mobilization and re-arrangement to ensure optimal reshaping with breast cosmesis \[[@B2-cancers-11-00253]\], the use of OPS (a form of breast reconstruction) has doubled from 2% to 5%. In parallel, mastectomy with implant placement (M + I) increased from 11% to 21% \[[@B1-cancers-11-00253]\]. Meanwhile, mastectomy with muscular flap reconstruction (M + MF) has actually declined from 4.5% to only 1% \[[@B1-cancers-11-00253]\]. Accompanying these changes in breast reconstruction is the steady decline of non-cosmetic procedures like traditional mastectomies (M). These shifting trends in breast cancer treatment are multifactorial and are likely attributed to changes in complication rates, comorbidities, patient demographics, patient surgical preference, and oncological guidelines for appropriate surgical resection \[[@B1-cancers-11-00253]\].

Breast reconstruction (OPS or M + R) offers patients an improved quality of life by providing an aesthetically symmetric breast together with higher patient satisfaction \[[@B2-cancers-11-00253],[@B3-cancers-11-00253],[@B4-cancers-11-00253]\]. Unfortunately, complication rates persist in breast cancer surgery and vary (2--40%) with the type of reconstruction. They also vary depending on whether we measure short-term or long-term outcomes \[[@B2-cancers-11-00253],[@B5-cancers-11-00253],[@B6-cancers-11-00253],[@B7-cancers-11-00253],[@B8-cancers-11-00253],[@B9-cancers-11-00253],[@B10-cancers-11-00253],[@B11-cancers-11-00253],[@B12-cancers-11-00253],[@B13-cancers-11-00253]\]. Fortunately, mortality in breast cancer surgery remains very low (\<1%) regardless of the type of surgery offered \[[@B14-cancers-11-00253]\]. Post-operative complications are influenced by multiple risk factors that surgeons should consider. Wound infections and postoperative infectious complications have been associated with smoking, prior radiation, obesity and diabetes \[[@B5-cancers-11-00253],[@B8-cancers-11-00253]\].

Several studies have also shown that multiple comorbidities and higher American Society of Anesthesiologist (ASA) classification predict higher complication rates following all surgery subtypes. Nevertheless, specifically pertaining to breast cancer intervention, many patient factors and surgical predictors thought to influence acute postoperative complications are unknown or controversial \[[@B5-cancers-11-00253],[@B8-cancers-11-00253],[@B15-cancers-11-00253],[@B16-cancers-11-00253],[@B17-cancers-11-00253]\]. Single institutional studies and prior reviews have generally suffered from small sample size and have lacked the power to adequately analyze the multiple variables influencing post-operative acute complications following breast cancer surgery.

Understanding surgical complications is crucial to patient safety and improving health care outcomes. Therefore, this study sought to examine the acute postoperative complication rates in breast cancer patients who underwent PM, M, M + I, M + MF, and OPS. Using the NSQIP database, we aimed to expand our understanding of predictive factors associated with different surgical procedures performed between 2005 and 2017 and evaluated trends over time.

2. Methods and Materials {#sec2-cancers-11-00253}
========================

This study follows the same methodology, inclusion/exclusion criteria, data collection and surgical categorization used in Jonczyk et al. \[[@B1-cancers-11-00253]\]. A retrospective cohort analysis was conducted using the ACS-NSQIP database from 2005 to 2017. All participant user files (PUF) were obtained and approved by ACS NSQIP. The Institutional Review Board deemed this study exempt from institutional review given that the ACS NSQIP database is a de-identified data set.

2.1. Data Collection {#sec2dot1-cancers-11-00253}
--------------------

Inclusion criteria for this study were women with classified post-operative diagnosis of invasive breast cancer (IvBC) or ductal carcinoma in-situ (DCIS) who underwent any BCT or any MAST procedure. Post-operative diagnosis was classified according to International Classification of Diseases Ninth Revision (ICD-9) code for IvBC (ICD-9, 174) or DCIS (ICD-9, 233). After October 2015, ICD Tenth Edition replaced the previous system of classification, and patients with IvBC or DCIS were classified under the appropriate ICD-10 codes: D05, D5.1-D05.99 (DCIS), and IvBC (C50). In order to examine complications for specific interventions, each surgical group (except for PM) was further divided into categories (CG) shown in [Table S1](#app1-cancers-11-00253){ref-type="app"}. A schematic of surgical (M, PM, OPS, M + R) categorization using CPT codes is shown in [Figure S1](#app1-cancers-11-00253){ref-type="app"}. Exclusion criteria included males, surgery for benign breast disease, lobular carcinoma in situ, patients undergoing breast cancer surgery with 2 CPT codes with ambiguous category placement and septic patients at time of surgery.

2.2. Complications and Outcome Measures {#sec2dot2-cancers-11-00253}
---------------------------------------

We identified 16 acute complications in the NSQIP database that were collected prospectively in a 30-day post-operative period. We used these complications and clustered them into eight groups based on their medical similarity. [Table 1](#cancers-11-00253-t001){ref-type="table"} depicts complication clustering and the individual complications included.

Demographics, patient comorbidities, and surgical factors were also collected for each surgical category ([Table 2](#cancers-11-00253-t002){ref-type="table"}). Body mass index (BMI) was not included in NSQIP and was therefore calculated using weight (lbs.) divided by squared height, multiplied by 703 \[[@B13-cancers-11-00253]\]. Each patient was categorized as: underweight (BMI \< 18.5), normal (BMI 18.5--25), overweight (BMI 25--30) or obese (BMI \> 30).

2.3. NSQIP Variable Definitions {#sec2dot3-cancers-11-00253}
-------------------------------

NSQIP defines patients at risk for bleeding due to any condition with deficiency of clotting elements (Vitamin K deficiency, hemophilia's, thrombocytopenia, or on chronic anticoagulation other than aspirin). Chemotherapy and radiation were defined as being administered pre-operatively for malignancy in less than 30 days and 90 days, respectively. Open wound infections (OWI) were any breach of skin integrity with or without cellulitis or purulent exudate when leaving the operating room and this included the use of drain devices or negative pressure wound devices. OWI did not include scabbed over wound or Band-Aid covered sores (break in skin), tracheostomy, oral sores and ostomies. For this analysis, we associated OWI with drain placement or wound vac placement. Recent weight loss was defined as greater than 10% unintentional loss of body weight. Hypertension (HTN) had to be documented, and patients had to be on medication for over 2 weeks prior to surgical intervention.

2.4. Statistics {#sec2dot4-cancers-11-00253}
---------------

All analyses were performed using R-Studio software. Chi-square tests analyses were performed for demographic and complication rate analysis. Smoothed linear regression was used to adjust a best fit line and then a non-parametric Mann- Kendall test was used to assess complication temporal trends. The variables in [Table 3](#cancers-11-00253-t003){ref-type="table"} were used as covariates for a stepwise logistical regression model for each clustered complication grouping.

Each covariate was analyzed for significance in a univariate logistical regression (*p* \< 0.05) for each clustered complication. All significant covariates were used in a multivariable logistical regression (MLR) to calculate the adjusted odds ratio (OR) for acquiring each complication. Each covariate was compared to its baseline covariate and a computed OR predicts an association to the baseline covariate. Patient baseline covariates used in the MLR were as follows: diabetes treated with IV insulin, white race, non-smokers and no prior smoking pack-years, older age (\>60 years old), pathology (DCIS), normal BMI, no PMH of bleeding disorder, renal failure, angina, CHF, HTN, or COPD, and no recent weight loss. Surgical baseline covariates used in MLR were as follows: inpatient admission status, ASA class 1, operative time \< 1 h, surgery (PM), no open wound infection, and no prior operation within 30 days. All results were considered significant at *p* values \< 0.05 level.

3. Results {#sec3-cancers-11-00253}
==========

3.1. Participant Pool and Demographics {#sec3dot1-cancers-11-00253}
--------------------------------------

Between 2005 and 2017, over 6 million patients were included in the NSQIP database and roughly 300,000 patients underwent breast cancer surgery. A total of 226,899 (77.9%) women met our inclusion criteria for the present analysis ([Table S2](#app1-cancers-11-00253){ref-type="app"}). Demographics, patient comorbidities, and surgical factors were significantly different (\<0.001) among all five groups ([Table 2](#cancers-11-00253-t002){ref-type="table"}). Compared to other groups, the M + I group had the highest incidence of younger patients and a lower incidence of the following preoperative indicators: lower ASA class, fewer open wound infections or systemic infections within 48 hours of surgery, and fewer prior operations in the last 30 days.

3.2. Overall Complication Rate and Trend Analysis {#sec3dot2-cancers-11-00253}
-------------------------------------------------

Cumulative complication rates were analyzed between 2005--2017 and clustered into their appropriate complication groups for each surgical intervention ([Table 4](#cancers-11-00253-t004){ref-type="table"}).

All complication clusters were significant (\<0.0001). The overall complication rates per surgical intervention were as follows: PM 2.25%, OPS 3.2%, M 6.56%, M + MF 13.04% and M + I 5.68%. Wound, infectious, respiratory, bleeding and thromboembolic complications were highest in the M + MF group. The M group had the highest rates of renal, cardiac and stroke complications. [Table 5](#cancers-11-00253-t005){ref-type="table"} and [Figure 1](#cancers-11-00253-f001){ref-type="fig"} depict the 13-year adjusted smoothed trend analysis in nationwide breast cancer surgeries.

From 2005 to 2017, there was no significant trend change for acute postoperative complications in all patients in the BCT group (PM and OcPs); (*p* \>0.05). However, all categories in the MAST group had increased trends for complication rates as follows: M category 5.4% to 6.8% (*p* = 0.004), M + I 5.5% to 6.1% (*p* = 0.02) and M + MF 7.4% to 13.3% (*p* = 0.01).

3.3. Independent Factors Associated with Complications (p \< 0.05) {#sec3dot3-cancers-11-00253}
------------------------------------------------------------------

Factors in the unadjusted analysis most likely associated with any complication were: outpatient surgery, increased BMI, smoking, M + R, OPS, ASA Class, increasing operative time, PMH of diabetics, renal failure, angina, CHF, COPD and HTN. Factors analyzed that were least likely to be associated with any cluster of complications included: pathology of the cancer, use of chemotherapy, PMH of dyspnea, angina or renal failure, prior operation in the last 30 days, pregnancy and recent pneumonia within 48 h. Unadjusted OR can be seen in [Table S3](#app1-cancers-11-00253){ref-type="app"}A--C, and significant covariates were used in the multiple linear regression (MLR). [Table 6](#cancers-11-00253-t006){ref-type="table"} and [Table 7](#cancers-11-00253-t007){ref-type="table"} show MLR analysis of predictive factors associated with patient characteristics and surgical predictors, respectively.

3.4. Adjusted Predictive Factors {#sec3dot4-cancers-11-00253}
--------------------------------

### 3.4.1. Predicting Factors Associated with Lower Complication Rates {#sec3dot4dot1-cancers-11-00253}

Complications had a lower associated risk when post-operatively treated as outpatients (decrease risk ranging from 16% to 87%) when compared to inpatients (*p* \< 0.03). Compared to diabetics on insulin therapy, diabetics on oral medication were 25% less likely to acquire wound complications and had a 26% lower incidence of other infections (*p* = 0.005; *p* \< 0.02). Likewise, non-diabetics reduced their odds of wound complications by 40%, infections by 41%, bleeding complications requiring transfusions by 45%, and renal complications by 67% (*p* \< 0.004). Younger patients (\<60 years of age) were 47% less likely to have cardiac complications (*p* = 0.02), 39% less likely to acquire respiratory complications, and had a 67% lower risk for stroke.

### 3.4.2. Predicting Factors Associated with Higher Complication Rates {#sec3dot4dot2-cancers-11-00253}

Smokers had a 1.6× higher odds of wound complications and 1.2× higher risk for infectious complications (*p* \< 0.03). Compared to patients with a normal BMI, increasing BMI (obese and overweight patients) correlated with more complications. Obese patients were more likely to have wound complications by a factor of 2.2, infections by a factor of 1.68, respiratory complications by a factor of 1.5, and thromboembolic complications by a factor of 1.66 (all *p* \< 0.03). However, underweight BMI patients had an increased risk of respiratory (2.22×) and cardiac (2.83) complications (both *p* \< 0.2). Preoperative unintentional weight loss was associated with increased infections by a factor of 3.46 (*p* = 0.04) and respiratory complication by a factor of 2.7 (*p* = 0.04). Steroidal use was associated with increased bleeding risk by a factor of 1.82 (*p* = 0.001).

Comorbidities correlated to an increased risk for five complication clusters: wound, infection, respiratory, bleeding and renal. COPD predicted a higher risk of wound complications by 1.29× (*p* = 0.003), infections by 1.36× (*p* = 0.02) and respiratory complication by 1.81× (*p* = 0.007). CHF increased odds of bleeding complications 3-fold (*p* = 0.0001) and renal complications 5-fold (*p* = 0.004). PMH of angina was associated with a two-fold risk of wound complications (*p* = 0.003) and cardiac complications risk 5.20× (*p* = 0.03). Hypertensive patients on medication were more likely to acquire infections by a factor of 1.2× (*p* = 0.005) and cardiac complications by a factor of 2.3× (*p* = 0.003). Patients were 10× more likely to have renal complication when having a PMH of renal failure (*p* = 0.03). Similarly, PMH of a bleeding disorder was associated with a two-fold odds of bleeding complications (\<0.0001), respiratory compromise (\<0.0001), infections (*p* = 0.0006) and renal complications (*p* = 0.03).

Perioperative surgical predictors were notable for an associated trend in numerous covariate categories. Overall, all MAST procedures were almost twice as likely to suffer from wound, infectious, bleeding, thromboembolic and neurological complications (*p* \< 0.002). Of note, M + MF was a particularly significant risk factor for predicting complications. There was a 10-fold increase for bleeding complications in the M + MF group (\<0.0001). A trend correlating increase in operative time was associated with increasing wound complications by 1.32--2.79× (*p* \< 0.0001), infections 1.34--2.55× (*p* \< 0.01), bleeding complications 2.9--7.16× (*p* \< 0.0001) and thromboembolic complications 1.95--6.36× (*p* \< 0.0001). Compared to surgical operative times of less than 1 h, operative times between 1 and 5 hours lowered the likelihood of cardiac complications by 43--73% and risk of stroke by 70% in some women. Rising ASA class 2--4 correlated with increased likelihood of acquiring a wound complications (*p* \< 0.02) and infections (*p* \< 0.004).

4. Discussion {#sec4-cancers-11-00253}
=============

The incidence of breast cancer in the United States continues to increase. Therefore, it has become increasingly important to address the complication rates resulting from unique patient demographics and comorbidities \[[@B18-cancers-11-00253]\]. In 1998, the Women's Health and Cancer Rights Act (WHCRA) offered patients protection and insurance coverage for reconstructive breast intervention following a mastectomy \[[@B19-cancers-11-00253]\]. Since then, reconstructive rates have increased dramatically. With this rise in breast reconstruction, studies outlining the risk factors associated with these modern surgeries have become a significant part of the surgical decision making process. To our knowledge, our study is the largest analysis of surgical trends with acute post-operative complications in all breast cancer interventions in context to IvBC and DCIS.

Our data analysis shows no overall complication trends in patients undergoing BCT. However, MAST procedures all have increasing trends for complication rates and M + MF had the highest complication rate in the majority of complication clusters. The diminishing use of M + MF may be the result of its prolonged operative time and higher acute complication rate. Within the MAST group, M + I had the lowest overall complication rate, even when compared to M alone. This is possibly attributed to its use in healthier patients as seen in patient demographics ([Table 2](#cancers-11-00253-t002){ref-type="table"}). Compared to previous single institution analyses, our data falls within previously described ranges of early or acute post-operative complications rates ranging as follows: PM 1.2--1.4% \[[@B20-cancers-11-00253],[@B21-cancers-11-00253]\], OPS 4.8--20% \[[@B16-cancers-11-00253],[@B20-cancers-11-00253],[@B21-cancers-11-00253],[@B22-cancers-11-00253],[@B23-cancers-11-00253]\], M 6% \[[@B14-cancers-11-00253]\], M + I 4--40% \[[@B6-cancers-11-00253],[@B8-cancers-11-00253],[@B24-cancers-11-00253]\], M + MF 16--23.7% \[[@B5-cancers-11-00253]\]. Varying with the type of reconstructive procedure, long-term complication rates (\>30 days) were typically higher \[[@B6-cancers-11-00253],[@B9-cancers-11-00253],[@B22-cancers-11-00253],[@B24-cancers-11-00253],[@B25-cancers-11-00253]\]. In our data, wound complications and infections represented the majority of overall complication rates in all surgical categories. Bleeding complications requiring transfusions were the third most common complication. The occurrence of a bleeding complication was 4.34% in M + MF, followed by 1.2% in M, 0.63% in M + I and 0.38% in OPS.

Overall, our analysis relates to and expands on previously published data demonstrating that patients undergoing OPS had the lowest complication rates when compared to patients undergoing M alone or M with any reconstructive procedure \[[@B20-cancers-11-00253],[@B21-cancers-11-00253],[@B23-cancers-11-00253],[@B26-cancers-11-00253],[@B27-cancers-11-00253],[@B28-cancers-11-00253]\]. OPS is gaining popularity due to its high aesthetic satisfaction, increased tumor free margin rate, and decreased recurrence rate when compared to other surgical interventions \[[@B1-cancers-11-00253],[@B15-cancers-11-00253],[@B16-cancers-11-00253],[@B22-cancers-11-00253],[@B26-cancers-11-00253],[@B29-cancers-11-00253]\]. The lower complication rate offers surgeons one more reason to offer OPS. For patients with large tumors located in the upper inner or lower poles of the breast, OPS is now frequently the recommended option \[[@B15-cancers-11-00253]\]. Conversely, mastectomy procedures encompass extensive tissue removal with the added difficulties of reconstruction and skin expansion. Previously reported analyses, specific for M + R, have found associated higher complication rates (up to 40%) including early infection, bleeding, wound dehiscence, scar formation, nipple loss, capsular contracture, flap loss and functional impairment \[[@B5-cancers-11-00253],[@B6-cancers-11-00253],[@B7-cancers-11-00253],[@B8-cancers-11-00253]\].

Similar to previously conducted retrospective studies, our data demonstrates increased acute complications rates associated with smoking \[[@B5-cancers-11-00253],[@B8-cancers-11-00253],[@B14-cancers-11-00253],[@B25-cancers-11-00253],[@B30-cancers-11-00253],[@B31-cancers-11-00253]\], obesity \[[@B5-cancers-11-00253],[@B8-cancers-11-00253],[@B14-cancers-11-00253],[@B25-cancers-11-00253],[@B30-cancers-11-00253],[@B31-cancers-11-00253]\] and advancing age \[[@B5-cancers-11-00253],[@B8-cancers-11-00253],[@B10-cancers-11-00253],[@B31-cancers-11-00253]\]. Our adjusted linear regression analysis found that, when compared to diabetics treated with insulin, non-diabetics and diabetics on oral medication only had a much lower incidence of multiple complications. This is in conflict with other retrospective analyses showing no significant difference between patients with and without glycemic control \[[@B8-cancers-11-00253],[@B25-cancers-11-00253],[@B32-cancers-11-00253]\]. Similarly, advancing age is a controversial factor for predicting acute complication rates. When adjusted for confounding health status and comorbidities, elderly patients have an increased likelihood to acquire a complication. These results were consistent with other studies \[[@B8-cancers-11-00253],[@B10-cancers-11-00253],[@B25-cancers-11-00253],[@B30-cancers-11-00253]\]. Radiation and chemotherapy were significant predictors in the univariate analysis for multiple complications; however, in adjusted MLR, they were insignificant confounders showing no risk of acute postoperative complication \[[@B33-cancers-11-00253]\].

Our data showed that extended operative times correlated with an additional 25% per hour increased likelihood of complications \[[@B8-cancers-11-00253],[@B14-cancers-11-00253],[@B31-cancers-11-00253],[@B34-cancers-11-00253]\]. Likewise, increasing ASA class doubled or tripled the likelihood for complications, especially wound complications and infections \[[@B8-cancers-11-00253],[@B14-cancers-11-00253],[@B31-cancers-11-00253],[@B35-cancers-11-00253]\]. Although surgeons consider comorbidities to be predictive of complications, there is minimal reliable breast cancer research on how certain patient factors including recent weight loss, type of surgical intervention, PMH of CHF, angina, HTN, COPD, renal failure, and bleeding disorders, affect health outcomes.

In the context of elective surgery, COPD, CHF and recent weight loss have been related to an increased risk of pulmonary complications \[[@B36-cancers-11-00253]\]. Intuitively, cardiovascular comorbidities such as hypertension (HTN), angina and CHF are associated with higher cardiac complications \[[@B37-cancers-11-00253],[@B38-cancers-11-00253]\]. Regarding readmission status following elective surgery, a two-fold increase has been associated with CHF \[[@B39-cancers-11-00253]\]. Our research closely parallels the results of previously published data on several risk factors associated with non-cardiac surgeries \[[@B36-cancers-11-00253],[@B37-cancers-11-00253],[@B38-cancers-11-00253],[@B39-cancers-11-00253]\]. For example, HTN increased odds two-fold (*p* = 0.003) for cardiac complications as did angina 5× (*p* = 0.03) and underweight BMI 3× (*p* = 0.02). Furthermore, wound and infectious complications nearly doubled in patients with comorbidities such as bleeding disorders, COPD, HTN, CHF and angina. Similarly, PMH of renal failure exaggerated renal complications ten-fold (*p* = 0.03) as did other comorbidities such as CHF, bleeding disorders and recent weight loss (albeit to a lesser extent). The same comorbidities also increased the likelihood of bleeding complications.

Identifying and quantifying these comorbidities preoperatively may allow for better stratification of patient risk and better matching of patients with different operative procedures in order to lower post-operative morbidity \[[@B40-cancers-11-00253]\]. It is logical to adhere to published guidelines on the classification and management of comorbid illnesses prior to surgery: optimizing COPD patients according to GOLD guidelines \[[@B41-cancers-11-00253],[@B42-cancers-11-00253]\], cardiovascular optimization of HTN, CHF, and angina according to the 2014 ACC/AHA guidelines \[[@B43-cancers-11-00253]\], and renal management according to guidelines from the Kidney Disease: Improving Global Outcomes (KDIGO) organization or American Society of Nephrology in order to minimize acute kidney injury post-operatively \[[@B44-cancers-11-00253],[@B45-cancers-11-00253],[@B46-cancers-11-00253]\].

Return to the OR is a factor in large part under a surgeon's control, done primarily for close/positive surgical margins or due to complications (current rate = 5%; see [Table 2](#cancers-11-00253-t002){ref-type="table"}). Following this review, and with enhanced knowledge of factors predictive of complications, appropriate action can be taken to further diminish them. Our predictors should allow surgeons to better consent patients and identify those at particular risk for specific complications. Patients with any drains or wound vacuum device placement are more likely to be at risk for a post-operative complication and should be counseled preoperatively We should always try to keep operative time to a minimum (when feasible) and recommend treating patients in the outpatient setting, as both factors were associated with fewer complications across all category types. Interestingly, despite the additional surgery, OPS was associated with the lowest complication rate (other than PM alone), and this factor should be considered in determining the optimal surgical approach for any patient considering mastectomy or mastectomy with reconstruction.

There were several limitations in this study. Oncologic factors, such as tumor size, preoperative nodal involvement, and stage, were not included in the dataset, thereby precluding us from determining their role in deciding the choice of surgical intervention. Interpretation of NSQIP database based on appropriate coding can be problematic, especially with the growing number of NSQIP and CPT codes for OPS. OPS as a reconstructive technique has gained popularity, but CPT codes may vary significantly from one institution to another. We used a coding protocol similar to one used at our institution---as OPS has no specific individual CPT code. Also, long term complications were not recorded in the NSQIP database, thereby potentially skewing the final data. Finally, certain comorbidities such as bleeding disorder and CHF may correlate with one another, but NSQIP did not provide specific medications like the purpose of blood thinners that may have affected these risks and rates of complications. This study highlights the on-going need for further, prospective studies that include the exact surgical procedure, patient comorbidities, and the concomitant use of chemotherapy and radiation therapy in order to help surgeons identify high-risk patients and lower postoperative complications.

5. Conclusions {#sec5-cancers-11-00253}
==============

As surgical interventions evolve according to oncological guidelines, patient preferences and modern reconstructive surgeries, the importance of determining and acknowledging complication rates is critical for every surgeon. This paper summarizes most of the risk factors and complications associated with the different kinds of breast surgery. While PM alone has the lowest complication rate (with positive margin rate not included as a complication), it is interesting to note that OPS offers both a form of breast reconstruction and a lower complication rate than either mastectomy alone or mastectomy with reconstruction. This factor should be taken into consideration when counseling patients who require more than a simple partial mastectomy.

The following are available online at <https://www.mdpi.com/2072-6694/11/2/253/s1>, Figure S1: Methods Schematic, Table S1: CPT Codes use to Categorize Breast Cancer Intervention, Table S2: Data from NSQIQ database. Table S3: Unadjusted Logistical Regression.

###### 

Click here for additional data file.
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Abbrev.

Definition

BCT

Breast Conservative Therapy

IvBC

Invasive Breast Cancer

DCIS

Ductal Carcinoma in situ

PM

Partial Mastectomy

M

Mastectomy

M + R

Mastectomy with reconstruction

OPS

Oncoplastic Surgery

M + I

Mastectomy with breast prosthesis, delayed-insertion or tissue expander for implant placement

M + MF

Mastectomy with Muscular Flap

MLR

Multivariable Logistical Regression

R2

Linear Regression

ACS

American College of Surgeons

NSQIP

National Surgical Quality Improvement Program

CPT

Current Procedural Terminology

ICD-9

International Classification of Diseases Ninth Revision

CG

Categories

![Annual trend analysis showing complication rate within each surgical category. PM: Partial Mastectomy; OPS: Oncoplastic Surgery; M: Mastectomy; M + MF: Mastectomy with Muscular Flap reconstruction; M + I: Mastectomy with Implant placement.](cancers-11-00253-g001){#cancers-11-00253-f001}

cancers-11-00253-t001_Table 1

###### 

Complication Clustered from NSQIP database.

  ---------------------------------------------------------------------------------------
  Clusters                       Individual Complication with NSQIP Code
  ------------------------------ --------------------------------------------------------
  Wound Complications            Superficial Incisional Infection SSI: SUPINFEC\
                                 Deep incisional Infection DSI: WNDINFD

  Infectious Complications       Organ/Space SSI: ORGSPCSSI\
                                 Urinary Tract Infection UTI: URNINFEC\
                                 Sepsis: OTHSYSEP\
                                 Septic Shock: OTHSESHOCK

  Respiratory Complications      Pneumonia: OUPNEUMO\
                                 Unplanned re-intubation: REINTUB

  Thromboembolic Complications   Pulmonary Embolism: PULEMBOL\
                                 DVT requiring Therapy: OTHDVT

  Bleeding Complications         Intraoperative or post-operative transfusion: OTHBLEED

  Renal Complications            Postoperative Renal Failure: OPRENAFL\
                                 Progressive Renal Insufficiency: RENAFAIL

  Cardiac Complications          Cardiac arrest requiring CPR: CDARREST\
                                 Myocardial infarction: CDMI

  Stroke Complications           Stroke: CNSCVA
  ---------------------------------------------------------------------------------------

cancers-11-00253-t002_Table 2

###### 

Patient Demographics and Comorbidities in each Surgical Category.

  ---------------------------------------------------------------------------------------------------------------------------------
  Demographics (%)                PM\                OPS\         M\             M + MF\      M + I\         *p*-Value   
                                  *n* = 95,468       *n* = 7279   *n* = 70,616   *n* = 4747   *n* = 44,093               
  ------------------------------- ------------------ ------------ -------------- ------------ -------------- ----------- ----------
  Age                             Young: \<60        56.63        54.71          42.19        75.27          78.25       \<0.0001

                                  Older: \>60        43.37        45.29          57.81        24.73          21.75       

  Race                            White              72.66        74.91          68.73        73.98          76.77       \<0.0001

                                  Black              10.71        11.84          11.83        12.79          7.99        

                                  Asian/Pacific      3.88         4.09           6.13         3.71           4.39        

                                  Native             0.50         0.16           0.72         0.21           0.22        

                                  Unknown            12.24        8.98           12.59        9.31           10.63       

  Pathology                       Invasive           78.46        81.04          86.58        78.83          80.29       \<0.0001

                                  DCIS               21.54        19.10          13.42        21.17          19.71       

  Admission Status                Inpatient          7.15         15.11          51.81        93.66          61.99       \<0.0001

                                  Outpatient         92.85        84.89          48.19        6.34           38.01       

  BMI                             Underweight        2.09         1.36           2.80         1.18           2.29        \<0.0001

                                  Normal             27.27        27.17          29.20        30.90          41.27       

                                  Overweight         30.55        29.43          29.35        33.85          28.72       

                                  Obese              40.07        29.43          38.65        34.02          27.71       

  Diabetic                        Non-Diabetic       86.91        88.68          84.24        93.22          94.60       \<0.0001

                                  Diabetic-Insulin   3.67         3.20           4.94         1.85           1.38        

                                  Diabetic-Oral      9.42         8.12           10.82        4.93           4.02        

  Pregnancy Status                0.03               0.00         0.06           0.04         0.02           \<0.0001    

  Steroid Use                     1.87               1.91         2.70           1.56         1.76           \<0.0001    

  Prior Chemotherapy              0.83               1.20         3.37           2.53         1.66           \<0.0001    

  Prior Radiation Therapy         0.08               0.04         0.26           0.34         0.09           \<0.0001    

  Recent Weight Loss              0.27               0.34         0.72           0.40         0.29           \<0.0001    

  PMH of Angina                   0.07               0.07         0.11           0.04         0.02           \<0.0001    

  PMH of Hypertension             0.47               0.40         0.50           0328         0.24           \<0.0001    

  PMH of CHF                      0.27               0.29         0.43           0.06         0.04           \<0.0001    

  PMH of Renal Failure            0.03               0.03         0.04           0.00         0.01           0.009       

  PMH of Bleeding Disorders       1.64               1.14         2.25           0.57         0.64           \<0.0001    

  PMH of COPD                     3.05               1.81         3.96           0.93         0.80           \<0.0001    

  Recent Pneumonia                0.01               0.00         0.01           0.00         0.00           \<0.0001    

  Dyspnea                         At Rest            0.29         0.08           0.42         0.06           0.06        \<0.0001

                                  Moderate           5.56         3.49           7.48         3.60           2.46        

                                  None               94.15        96.43          92.11        96.33          97.48       

  ASA Class                       1                  6.19         5.19           3.74         6.38           7.88        \<0.0001

                                  2                  58.95        60.35          51.60        69.20          69.34       

                                  3                  33.25        33.48          42.22        24.04          21.69       

                                  4                  1.36         0.80           2.33         0.32           0.30        

                                  5                  0.00         0.00           0.00         0.00           0.00        

  Open Wound Infection            0.37               0.25         1.31           1.22         0.20           \<0.0001    

  Prior Infection                 SIRS               0.20         0.23           0.42         0.55           0.23        \<0.0001

  (Within 48 h)                   Sepsis             0.01         0.01           0.04         0.06           0.00        

  Any Operation in Last 30 Days   1.92               0.91         1.30           2.19         0.66           \<0.0001    

  Operating Time                  Less than 1 h      0.48         0.16           0.13         0.01           0.01        \<0.0001

                                  1--2 h             0.42         0.37           0.47         0.04           0.11        

                                  2--3 h             0.08         0.23           0.12         0.07           0.29        

                                  3--5 h             0.02         0.18           0.02         0.34           0.45        

                                  5--10 h            0            0.05           0            0.47           0.12        

                                  10+ h              0            0              0            0.06           0           

  Return to OR (Within 30 Days)   0.05               0.04         0.04           0.08         0.07           \<0.0001    
  ---------------------------------------------------------------------------------------------------------------------------------
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###### 

Covariates used in Multivariable Logistical Regression.

  -----------------------------------------------------------------------------
  Surgery Type                      PM \*\*, OPS, M, M + R, M + I
  --------------------------------- -------------------------------------------
  Age                               Young: \<60\
                                    Older: \>60 \*\*

  Race                              White \*\*, Black, Asian, Native, Unknown

  Pathology                         Invasive Breast Cancer\
                                    Ductal Carcinoma in situ \*\*

  Admission Status                  Inpatient \*\* or Outpatient

  BMI                               Underweight\
                                    Normal \*\*\
                                    OverweightObese

  Pregnancy Status                  Yes or No \*\*

  Smoking Status                    Smoker or Non-Smoker \*\*

  Smoking Pack Per Day (PPD)        None \*\*\
                                    0--20 PPD\
                                    21--50 PPD\
                                    50--100 PPD\
                                    \>100 PPD

  Steroid Use                       Yes or No \*\*

  Prior Chemotherapy                Yes or No \*\*

  Prior Radiation Therapy           Yes or No \*\*

  Peri-Operative ASA Class          1 \*\*, 2, 3, 4, 5

  Operative Wound Infection         Yes or No \*\*

  Any Operation in Last 30 Days     Yes or No \*\*

  Recent Pneumonia                  Yes or No \*\*

  Diabetic                          Non-Diabetic\
                                    Diabetic on Insulin \*\*\
                                    Diabetic on Oral medication

  Recent Weight Loss                Yes or No \*\*

  PMH of Angina                     Yes or No \*\*

  PMH of Congestive Heart Failure   Yes or No \*\*

  PMH of Renal Failure              Yes or No \*\*

  PMH of COPD                       Yes or No \*\*

  History of Bleeding Disorder      Yes or No \*\*

  Operating Time                    Less than 1 h \*\*\
                                    1--2 h\
                                    2--3 h\
                                    3--5 h\
                                    5--10 h\
                                    Over 10 h
  -----------------------------------------------------------------------------

\* The regression model provides odds ratios compared to a baseline covariate. The asterisks \*\* is the baseline covariate.

cancers-11-00253-t004_Table 4

###### 

Complication rate in Surgical interventions.

  -----------------------------------------------------------------------------------------------------------------------------------------------
  Categories →\               BCT *n* = 102,747   MAST *n* = 119,456   *p*-Value                                                       
  Complication (*n*, %)                                                                                                                
  --------------------------- ------------------- -------------------- ----------- ------ ------ ------- ----- -------- ------ ------- ----------
  Wound Complication          1341                1.40                 128         1.76   2385   3.38    244   5.14     1325   3.01    \<0.0001

  Infectious                  456                 0.48                 50          0.69   823    1.17    92    1.94     652    1.48    \<0.0001

  Respiratory                 90                  0.09                 8           0.11   172    0.24    12    0.25     43     0.10    \<0.0001

  Bleeding                    66                  0.07                 28          0.38   844    1.20    206   4.34     277    0.63    \<0.0001

  Thromboembolic              99                  0.10                 9           0.12   200    0.28    55    1.16     179    0.41    \<0.0001

  Renal                       21                  0.02                 2           0.03   53     0.08    3     0.06     11     0.02    \<0.0001

  Cardiac                     42                  0.04                 4           0.05   89     0.13    3     0.06     8      0.02    \<0.0001

  Stroke                      29                  0.03                 4           0.05   64     0.09    4     0.08     10     0.02    \<0.0001

  Overall Complication Rate   2144                2.25%                233         3.2%   4630   6.56%   619   13.04%   2505   5.68%   \<0.0001
  -----------------------------------------------------------------------------------------------------------------------------------------------

BCT. Breast conservation therapy; MAST: Mastectomy group; PM: Partial Mastectomy; OcPs: Oncoplastic Surgery; M: Mastectomy; +MF: Mastectomy with Muscular Flap reconstruction; M + I: Mastectomy with Implant placement.
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###### 

Trend of Surgical Complication Rates (*n*, %) \*.

  Year                         Trend of Surgical Complication Rates (*n*, %) \*                                                                            
  ---------------------------- -------------------------------------------------- ------ -------- ------ -------- ------- -------- ------ -------- ------- --------
  2005                         22                                                 2.7%   1        2.8%   32       5.4%    11       5.5%   4        7.4%    
  2006                         68                                                 2.5%   3        1.6%   112      5.5%    30       5.6%   17       7.4%    
  2007                         103                                                2.4%   1        2.7%   193      5.6%    73       5.1%   24       8.5%    
  2008                         110                                                2.3%   7        3.7%   254      5.9%    91       5.0%   38       8.4%    
  2009                         119                                                2.2%   11       3.7%   326      6.4%    119      5.1%   35       10.7%   
  2010                         115                                                2.1%   6        3.6%   340      6.9%    147      5.6%   54       13.2%   
  2011                         129                                                2.1%   15       3.2%   331      7.0%    192      6.0%   64       16.0%   
  2012                         151                                                2.2%   16       3.1%   359      6.8%    224      5.8%   58       16.5%   
  2013                         177                                                2.1%   16       2.7%   391      6.6%    249      5.6%   56       16.8%   
  2014                         199                                                2.3%   21       3.1%   422      6.7%    252      5.5%   54       16.7%   
  2015                         276                                                2.3%   37       3.1%   436      6.9%    280      5.7%   47       14.7%   
  2016                         278                                                2.3%   33       3.4%   494      6.8%    320      5.9%   34       13.8%   
  2017                         295                                                2.2%   45       3.2%   434      6.8%    340      6.1%   41       13.3%   
  **Overall Trend Analysis**                                                                                                                               
  *p*-Value                    (R^2^)                                             0.29   (0.27)   0.67   (0.14)   0.004   (0.71)   0.02   (0.39)   0.01    (0.60)

\* Percentages are taken from smoothed data analysis to assess trend.
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###### 

Multivariable Logistical Regression Analysis of 30-Day Complication Rate: Patient Characteristics and Demographic Predictors.

  ----------------------------------------------------------------------------------------------------------------------
  Complication                   OR (95% CI)                 Complication                    OR (95% CI)
  ------------------------------ --------------------------- ------------------------------- ---------------------------
  Wound Complications\           \                           Infectious Complications\       \
  Protective\                    \                           Protective\                     \
  Diabetic on Oral medication\   0.75 (0.63--0.88) \*\*\     Diabetic on Oral medication\    0.74 (0.56--0.97) \*\
  Non-Diabetic                   0.61 (0.53--0.70) \*\*\*    Non-Diabetic                    0.62 (0.49--0.78) \*\*\*

  Risk                                                       Risk                            

  PMH of Angina\                 2.22 (1.24--3.98) \*\*\     PMH of CHF\                     2.13 (1.17--3.89) \*\
  PMH of COPD\                   1.29 (1.09--1.53) \*\*\     PMH of COPD\                    1.34 (1.02--1.76) \*\
  PMH of Bleeding Disorder\      1.44 (1.17--1.77) \*\*\     PMH of Bleeding Disorder\       1.73 (1.27--2.35) \*\*\
  Smoker\                        1.61 (1.46--1.77) \*\*\*\   PMH of HTN\                     1.20 (1.06--1.37) \*\*\
  BMI Obese\                     2.17 (1.97--2.38) \*\*\*\   BMI: Overweight\                1.36 (1.16--1.63) \*\*\
  BMI: Overweight                1.34 (1.21--1.48) \*\*\*    BMI ObeseRecent Weight Loss     1.62 (1.39--1.90) \*\*\*\
                                                                                             3.48 (2.24--5.42) \*\*\*

  Respiratory Complications\     \                           Bleeding Complications\         \
  Protective\                    \                           Protective\                     \
  Age \<60                       0.66 (0.47--0.93) \*        Non-Diabetic                    0.65 (0.49--0.89) \*\*

  Risk                                                       Risk                            

  PMH of COPD\                   1.80 (1.14--2.85) \*\       Recent Weight Loss\             1.96 (1.02--3.79) \*\
  BMI: underweight\              2.25 (1.14--4.42) \*\       PMH of CHF\                     2.97 (1.67--5.26) \*\
  Recent Weight Loss\            2.76 (1.09--6.99) \*\       Steroid Use\                    1.82 (1.26--2.62) \*\*\
  PMH of Bleeding Disorder       2.70 (1.67--4.36) \*\*\*    PMH of Bleeding Disorder        2.62 (1.90--3.62) \*\*\*

  Neuro Complications\           \                           Thromboembolic Complications\   \
  Protective\                    \                           Risk\                           \
  Age \<60                       0.14 (0.06--0.32) \*\*\*    BMI: Overweight\                1.66 (1.18--2.36) \*\*\
                                                             BMI: Obese                      2.45 (1.77--3.40) \*\*\*

  Renal Complications\           \                           Cardiac Complications\          \
  Protective\                    \                           Protective\                     \
  Non-Diabetic                   0.35 (0.18--0.71) \*\*      Age \<60                        0.53 (0.30--0.91) \*

  Risk                                                       Risk                            

  PMH of Bleeding Disorder\      2.50 (1.05--5.94) \*\       BMI: Underweight\               2.94 (1.23--7.03) \*\
  PMH of Renal Failure\          10.45 (1.19--91.74) \*\     PMH of Angina\                  5.20 (1.20--22.46) \*\
  PMH of CHF\                    5.06 (1.64--15.59) \*\*\    PMH of HTN                      2.34 (1.33--4.12) \*\*
  Recent Weight Loss             8.39 (2.87--24.53) \*\*                                     
  ----------------------------------------------------------------------------------------------------------------------

*p*-values: \* *p* \< 0.05; \*\* *p* \< 0.01--0.001; \*\*\* *p* \< 0.0001.
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###### 

Multivariable logistical Regression Analysis of 30-Day Complication Rate: Surgical Predictors of Morbidity.

  Complication                     OR (95% CI)                Complication               OR (95% CI)                Complication                OR (95% CI)
  -------------------------------- -------------------------- -------------------------- -------------------------- --------------------------- ----------------------------
  Wound Complications                                         Infectious Complications                              Bleeding Complications      
  Protective                                                  Protective                                            Protective                  
  Outpatient                       0.84 (0.77--0.91) \*\*\*   Outpatient                 0.74 (0.64--0.85) \*\*\*   Outpatient                  0.20 (0.16--0.6) \*\*\*
  Risk                                                        Risk                                                  Risk                        
  M                                1.79 (1.62--1.98) \*\*\*   M                          1.78 (1.48--2.13) \*\*\*   OPS                         2.78 (1.20--6.45) \*
  M + MF                           2.24 (1.83--2.74) \*\*\*   M + MF                     2.24 (1.60--3.13) \*\*\*   M + I                       3.61 (2.28--5.73) \*\*\*
  M + I                            1.72 (1.51--1.96) \*\*\*   M + I                      2.17 (1.73--2.72) \*\*\*   M                           5.78 (3.83--8.72) \*\*\*
  ASA2                             1.22 (1.02--1.48) \*       ASA2                       1.66 (1.14--2.40) \*\*     M + MF                      10.99 (6.73--17.90) \*\*\*
  ASA3                             1.57 (1.29--1.91) \*\*\*   ASA3                       2.44 (1.67--3.58) \*\*\*   ASA3                        2.18 (1.41--3.37) \*\*
  ASA4                             1.67 (1.23--2.26) \*\*     ASA4                       4.09 (2.50--6.67) \*\*\*   ASA4                        5.32 (3.12--9.08) \*\*\*
  Open Wound                       1.83 (1.40--2.39) \*\*\*   Open Wound                 1.98 (1.33--2.94) \*\*     Open Wound                  2.09 (1.36--3.21) \*\*
  OPT1                             1.32 (1.18--1.48) \*\*\*   OPT2.                      1.36 (1.09--1.71) \*       OPT4.                       2.92 (1.99--4.28) \*\*\*
  OPT2                             1.51 (1.33--1.72) \*\*\*   OPT3.                      1.70 (1.34--2.17) \*\*\*   OPT5.                       7.21 (4.22--12.33) \*\*\*
  OPT3                             1.75 (1.52--2.02) \*\*\*   OOPT4.                     2.55 (1.90--3.42) \*\*\*                               
  OPT4                             2.14 (1.78--2.57) \*\*\*   OPT5.                      2.64 (1.30--5.37) \*                                   
  OPT5                             2.81 (1.85--4.27) \*\*\*                                                                                     
  Thromboembolic Complications                                Cardiac Complications                                 Respiratory Complications   
  Protective                                                  Protective                                            Protective                  
  Outpatient                       0.70 (0.52--0.95) \*       Outpatient                 0.20 (0.11--0.35) \*\*\*   Outpatient                  0.24 (0.16--0.35) \*\*\*
  Risk                                                        M + I                      0.17 (0.04--0.83) \*       Risk                        
  M                                2.04 (1.37--3.02) \*\*     OPT1                       0.59 (0.35--0.97) \*       ASA4                        6.62 (2.14--20.48) \*\*
  M + MF                           3.91 (2.16--7.07) \*\*\*   OPT2                       0.47 (0.24--0.93) \*                                   
  M + I                            2.15 (1.33--3.47) \*\*     OPT3                       0.28 (0.09--0.86) \*                                   
  Prior operation within 30 days   3.20 (1.97--5.20) \*\*\*   Risk                                                                              
  OPT3                             1.95 (1.16--3.27) \*       ASA4                       10.31 (1.23--86.12) \*                                 
  OPT4                             3.40 (1.89--6.09) \*\*\*                                                                                     
  OPT5                             6.08 (2.41--15.32) \*\*    Renal Complications                                   Neuro Complications         
                                                              Protective                                            Protective                  
                                                              Outpatient                 0.26 (0.13--0.52) \*\*     Outpatient                  0.45 (0.26--0.81) \*\*
                                                                                                                    OPT2                        0.29 (0.12--0.71) \*\*
                                                                                                                    Risk                        
                                                                                                                    OPS                         4.58 (1.28--16.35) \*
                                                                                                                    M                           2.61 (1.31--5.21) \*\*

*p*-values. \* *p* \< 0.05; \*\* *p* \< 0.01--0.001; \*\*\* *p* \< 0.0001; ASA2: Class 2 Mild Disease, ASA 3: Class 3 Severe Disease, ASA4: Class 4 Severe Life Threatening; Operative time: OPT1: 1--2 h; OPT2: 2--3 h; OPT:3: 3--5 h; OPT4: 5--10 h; OPT5: \>10 h.
